Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy
{{output}}
Background: Ciltacabtagene autoleucel (cilta-cel) was approved for patients with relapsed or refractory multiple myeloma who received 1-3 prior lines of therapy in April 2024. Although traditionally administered inpatient (IP), there is an increasing trend in ... ...
